Dalim Fromtech

Dalim Fromtech is a South Korean biotechnology company specializing in the development of autophagy-based therapeutics for chronic and degenerative diseases. Founded in 2019 and acquired by Dalim Biotech in August 2024, the company leverages its proprietary autophagy-targeting chimera (AUTAC) platform to design small molecule degraders that selectively clear pathogenic proteins and alleviate lysosomal stress. Its research pipeline primarily focuses on treatments for Alzheimer's disease (targeting Tau protein and amyloid-beta), non-alcoholic steatohepatitis (NASH), and diabetes. Through collaborations with leading academic institutions like Yonsei University and Gachon University, Dalim Fromtech is advancing novel candidates, such as the Tau-specific autophagic degrader TA-3, to address significant unmet clinical needs.